文献速递消化、代谢与肾脏急症

憩室炎:综述

Diverticulitis: A Review.
PubMed 文献 · JAMA · 2025-07-24
一句话结论无并发症憩室炎一线为观察和镇痛,抗生素仅用于持续发热、白细胞升高、脓毒症、高龄、妊娠、免疫抑制及特定慢性病患者;有并发症者需静脉抗生素并视情况引流或手术。

本文综述憩室炎的流行病学、危险因素、诊断与治疗。美国年发病率约180/10万,每年约20万住院,医疗支出超63亿美元/年。约1%~4%憩室病患者一生中发生急性憩室炎,典型表现为左下腹痛伴恶心、呕吐、发热和白细胞增多。推荐行增强腹盆腔CT诊断,敏感度98%~99%、特异度99%~100%。约85%为无并发症憩室炎,处理为观察、镇痛(通常对乙酰氨基酚)和清流质饮食;抗生素用于有全身症状、白细胞进行性升高、年龄>80岁、妊娠、免疫功能受损及特定慢性病患者。有并发症者需静脉抗生素,必要时经皮引流或结肠切除;弥漫性腹膜炎应急诊剖腹探查加结肠切除。择期结肠切除术后死亡率0.5%,急诊结肠切除为10.6%。

要点

  • 无并发症憩室炎(无脓肿、狭窄、穿孔或瘘)首选观察、镇痛(通常对乙酰氨基酚)和清流质饮食,不常规用抗生素。
  • 抗生素指征:持续发热或寒战、白细胞进行性升高、年龄>80岁、妊娠、免疫功能受损(化疗、大剂量类固醇或器官移植)及肝硬化、慢性肾病、心衰、控制不佳的糖尿病等慢性病。
  • 诊断推荐增强腹盆腔CT,敏感度98%~99%、特异度99%~100%。
  • 有并发症憩室炎用静脉抗生素如头孢曲松+甲硝唑或哌拉西林-他唑巴坦,并视指征经皮引流脓肿或结肠切除。
  • 弥漫性腹膜炎应急诊剖腹探查加结肠切除;择期结肠切除术后死亡率0.5%,急诊结肠切除为10.6%。

适用人群与场景

  • 憩室病患者,约1%~4%一生中发生急性憩室炎。
  • 危险因素包括年龄>65岁、TNFSF15基因变异等遗传因素、多囊肾/马凡综合征/埃勒斯-当洛斯综合征等结缔组织病、体重指数≥30、使用阿片类/类固醇/非甾体抗炎药、高血压及2型糖尿病。

诊断标准与关键阈值

  • 无并发症憩室炎定义为 absence of abscess、结肠狭窄、结肠穿孔或瘘形成。
  • 有并发症憩室炎指存在脓肿、结肠狭窄、结肠穿孔或瘘形成。

处置流程与药物剂量

  • 无并发症憩室炎:观察、镇痛(通常对乙酰氨基酚)和清流质饮食。
  • 抗生素用于有全身症状(如持续发热或寒战)、白细胞进行性升高、年龄>80岁、妊娠、免疫功能受损(化疗、大剂量类固醇或器官移植)及慢性病(肝硬化、慢性肾病、心衰、控制不佳的糖尿病)患者。
  • 一线口服抗生素:阿莫西林/克拉维酸或头孢氨苄+甲硝唑。
  • 不能口服者用静脉抗生素:头孢呋辛或头孢曲松+甲硝唑,或氨苄西林/舒巴坦。
  • 有并发症憩室炎:静脉抗生素如头孢曲松+甲硝唑或哌拉西林-他唑巴坦,并视指征经皮引流腹腔脓肿或结肠切除。
  • 弥漫性腹膜炎:急诊剖腹探查加结肠切除。

红旗征与不能漏的情况

  • 弥漫性腹膜炎应急诊剖腹探查加结肠切除。
  • 持续发热或寒战、白细胞进行性升高提示需用抗生素。
  • 免疫功能受损、妊娠、年龄>80岁及特定慢性病患者需用抗生素。

研究设计与关键结果

  • 美国憩室炎年发病率约180/10万,每年约20万住院,医疗支出超63亿美元/年。
  • 约1%~4%憩室病患者一生中发生急性憩室炎,典型表现为左下腹痛伴恶心、呕吐、发热和白细胞增多。
  • 增强腹盆腔CT诊断敏感度98%~99%、特异度99%~100%。
  • 约85%急性憩室炎为无并发症。
  • 择期结肠切除术后死亡率0.5%,急诊结肠切除为10.6%。

证据类型、等级与局限

  • 证据类型:综述。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 无并发症憩室炎可仅观察、镇痛和清流质饮食,不常规用抗生素。
  • 抗生素仅用于有全身症状、白细胞进行性升高、年龄>80岁、妊娠、免疫功能受损及特定慢性病患者。
  • 有并发症憩室炎需静脉抗生素,并视指征经皮引流或结肠切除;弥漫性腹膜炎应急诊手术。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Diverticulosis is defined by the presence of multiple outpouchings (diverticula) originating from the intestinal lumen. Diverticulitis is defined as inflammation of these diverticula. The annual incidence of diverticulitis in the US is approximately 180 per 100 000 people, resulting in approximately 200 000 hospital admissions annually and an estimated health care expenditure of more than $6.3 billion/year.

OBSERVATIONS: Risk factors for diverticular disease include age older than 65 years, genetic factors such as variant in the tumor necrosis factor superfamily member 15 (TNFSFI5) gene; connective tissue diseases such as polycystic kidney disease, Marfan syndrome, or Ehlers-Danlos syndrome; body mass index 30 or greater; use of opioids, steroids, and nonsteroidal anti-inflammatory medications; hypertension; and type 2 diabetes. Approximately 1% to 4% of patients with diverticulosis will develop acute diverticulitis in their lifetime, which typically presents as left lower quadrant pain associated with nausea, vomiting, fever, and leukocytosis. A contrast-enhanced abdominal and pelvic computed tomography scan is the recommended diagnostic test and has a sensitivity of 98% to 99% and specificity of 99% to 100%. Approximately 85% of people with acute diverticulitis have uncomplicated diverticulitis (absence of abscess, colon strictures, colon perforation, or fistula formation). Management of patients with uncomplicated diverticulitis consists of observation with pain management (typically acetaminophen) and dietary modification with a clear liquid diet. Antibiotics should be reserved for patients with systemic symptoms such as persistent fever or chills, those with increasing leukocytosis, those older than 80 years, those who are pregnant, those who are immunocompromised (receiving chemotherapy, or high-dose steroids, or have received an organ transplant), and those with chronic medical conditions (such as cirrhosis, chronic kidney disease, heart failure, or poorly controlled diabetes). First-line antibiotics consist of oral amoxicillin/clavulanic acid or cefalexin with metronidazole. For patients who cannot tolerate oral intake, intravenous antibiotic therapy (ie, cefuroxime or ceftriaxone plus metronidazole or ampicillin/sulbactam) is appropriate. Complicated diverticulitis is managed with intravenous antibiotics such as ceftriaxone plus metronidazole or piperacillin-tazobactam and additional invasive management as indicated (ie, percutaneous drainage of associated intra-abdominal abscess or colon resection). Patients with generalized peritonitis should undergo emergent laparotomy with colonic resection. Postoperative mortality for diverticulitis managed electively or emergently is 0.5% for elective colon resection and 10.6% for emergent colon resection.

CONCLUSIONS AND RELEVANCE: In the US, diverticulitis affects approximately 180 per 100 000 people annually. For uncomplicated diverticulitis, first-line therapy is observation and pain control, and antibiotics should be initiated for patients with persistent fevers, increasing leukocytosis, sepsis or septic shock, advanced age, pregnancy, immunocompromise, and certain chronic medical conditions. Treatment of complicated diverticulitis includes intravenous antibiotics, such as ceftriaxone plus metronidazole or piperacillin-tazobactam, and, if indicated, percutaneous drainage of abscess or resection of diseased segment of colon.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Brown RF, Lopez K, Smith CB, et al. Diverticulitis: A Review. JAMA. 2025. PMID: 40705318. doi:10.1001/jama.2025.10234

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。